Sign In
NewsRadar

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.

   


PolyTechnos appoints Christian Schneider to Managing Partner/Successful IPO OncoMethylome Sciences


PolyTechnos Venture-Partners (“PolyTechnos”) is pleased to announce the promotion of Christian Schneider from Partner to Managing Partner as of 01 July 2006 as well as the completed IPO of its advised-funds’ portfolio company OncoMethylome Sciences S.A., a molecular diagnostics company with activities in Belgium, the Netherlands, and the U.S.

Christian Schneider promoted to Managing Partner

Christian Schneider, Ph.D., DVM, MBA, joined PolyTechnos in 2001 as Investment Manager and was promoted to Partner in July 2002. As the lead Partner for PolyTechnos’ advised funds’ portfolio company OncoMethylome Sciences (Euronext, Brussels and Amsterdam: ONCO), he has played a key role in shaping and implementing the company’s strategy. OncoMethylome Sciences went public on the Euronext stock exchanges of Brussels and Amsterdam on 27 June 2006. Christian actively applied his expertise in medical product development and diagnostics on the board of OncoMethylome Sciences and in his board observer roles at Devgen (Euronext, Brussels: DEVG) and Jerini (Frankfurt Stock Exchange: JI4) prior to their IPOs in June 2005 and November 2005, respectively.

Before joining PolyTechnos, Christian worked with Centocor, U.S., a Johnson & Johnson company, in external R&D management, business development, operations, diagnostic and biotechnology R&D, and technology transfer. He specialized in oncology, immunology, and cardiology product development. Christian was a doctoral research fellow at Boehringer Mannheim, Germany (now Roche Diagnostics). He holds a doctorate degree in veterinary medicine and a Ph.D. in immunology, both from the University of Munich, as well as an MBA with focus on healthcare administration from Pennsylvania State University, Pennsylvania, U.S. In addition, Christian is a U.S.-certified ISO-9000 Lead Assessor.

Dirk Kanngiesser, PolyTechnos Founder and Managing Partner, comments: “Since his joining, Christian has considerably contributed to PolyTechnos’ development to become one of the leading venture capital players in Europe. He was involved in three IPOs of our advised funds’ portfolio companies. On behalf of all Managing Partners, I would like to express our thanks for his dedicated contribution to create value for our funds. We all look forward to a continuing enjoyable and successful cooperation”.

OncoMethylome Sciences S.A. successfully completes IPO at Euronext

OncoMethylome Sciences went public at Euronext Brussels and Euronext Amsterdam on 27 June 2006 (Euronext: ONCO). The company was co-founded by PolyTechnos in 2003 with headquarters in Liège, Belgium, and subsidiaries in Amsterdam, the Netherlands, and Durham, North Carolina, U.S.. OncoMethylome Sciences develops patent-protected molecular tests to assist physicians in effectively detecting and treating cancer. Specifically, the company’s tests are designed to help the physician accurately detect cancer in early stages of cancer development, predict a patient’s response to drug therapy, and predict the likelihood of cancer recurrence.

With its IPO, the company has issued 3,373,334 new shares for a total amount of EUR 25.3 million, including the full exercise of a 15% greenshoe option, at a price of EUR 7.50 per share. The total number of outstanding shares now amounts to 10,450,954. The offering was organized by ING and Fortis as joint book runners and joint lead managers and Kempen & Co as co-manager. The new funds raised will enable the company to further execute its strategy and develop novel molecular tests in order to improve cancer patient care.

CEO Herman Spolders: “The fact that we were able to close our IPO in today’s challenging market conditions reflects the positive feedback we received from the investment community about the quality of our company and its broad product pipeline. We are proud to be the first Eurolist Brussels listing this year […]”.

With OncoMethylome Sciences, PolyTechnos’ advised funds broug


Publisher Contact Information:

PolyTechnos Venture-Partners GmbH
+49-89-242262-23
andrea.baechle@polytechnos.com

Company profile of PolyTechnos Venture-Partners GmbH
Past press releases of PolyTechnos Venture-Partners GmbH.

Data


26,254
Tech investments
From our Online Data Service
16,957
VC-backed companies
From our Radar


Recent Deals


DATEAMOUNTSECTOR
Oct 19€3.0MInternet services
Oct 19€6.0MBusiness applications
Oct 18€11.0MConsumer electronics
Oct 18€5.0MBusiness applications
Oct 17€5.9MBiopharmaceuticals
Oct 16€3.7MContent management
Oct 16€7.8MSensors

For information on Europe's most extensive database on technology funding click here!

Events



Press Releases


May 28
Identiq
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
Nethone
nethone raised over $1 million from innovation nest

Oct 1
The Link App
the link app launches version 2.0

Mar 29
Addex Therapeutics
addex sucessfully raises chf40 million in capital increase

Jan 2
Urban Jungle
urban jungle raises £1m in seed funding to build tech-enabled home ...





About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.